| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future.
|
Pediatr Blood Cancer
|
2005
|
1.22
|
|
2
|
Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group.
|
Pediatr Blood Cancer
|
2008
|
1.07
|
|
3
|
Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report.
|
Biol Blood Marrow Transplant
|
2007
|
1.05
|
|
4
|
Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
|
Pediatr Blood Cancer
|
2005
|
1.01
|
|
5
|
The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes.
|
Leuk Lymphoma
|
2007
|
0.90
|
|
6
|
B-Cell non-Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report.
|
Clin Adv Hematol Oncol
|
2003
|
0.86
|
|
7
|
B large-cell lymphoma in children and adolescents.
|
Cancer Treat Rev
|
2003
|
0.80
|
|
8
|
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
|
Br J Haematol
|
2005
|
0.75
|
|
9
|
Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.
|
Br J Haematol
|
2007
|
0.75
|
|
10
|
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
|
Clin Cancer Res
|
2005
|
0.75
|